PDGFRA and sarcoma: It shows that expression of these ligands and receptors correlate with sarcoma patient outcomes and indicates that differential expression of the ligands may constitute relevant biomarkers of efficacy of PDGFRα antibodies in this heterogeneous family of diseases.